Rajasekaran A, et al. IgA nephropathy: An interesting autoimmune kidney disease. Am J Med Sci 2021; 361:176–194. doi: 10.1016/j.amjms.2020.10.003

• PubMed
Rajasekaran A, IgA nephropathy: An interesting autoimmune kidney disease. Am J Med Sci 2021; 361:176–194. doi: 10.1016/j.amjms.2020.10.003 )| false
• Search Google Scholar
• Export Citation

Thompson A, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol 2019; 14:469–481. doi: 10.2215/CJN.08600718

• PubMed
Thompson A, Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol 2019; 14:469–481. doi: 10.2215/CJN.08600718 )| false
• Search Google Scholar
• Export Citation

Rovin BH, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:753–779. doi: 10.1016/j.kint.2021.05.015

• PubMed
Rovin BH, Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:753–779. doi: 10.1016/j.kint.2021.05.015 )| false
• Search Google Scholar
• Export Citation

Lv J, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 2022; 327:1888–1898. doi: 10.1001/jama.2022.5368

• PubMed
Lv J, Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 2022; 327:1888–1898. doi: 10.1001/jama.2022.5368 )| false
• Search Google Scholar
• Export Citation

Barratt J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int [published online ahead of print October 19, 2022]. https://www.sciencedirect.com/science/article/pii/S0085253822008365

• PubMed
Barratt J, Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int [published online ahead of print October 19, 2022]. https://www.sciencedirect.com/science/article/pii/S0085253822008365 )| false
• Search Google Scholar
• Export Citation

Wong M, et al. MO209: Baseline characteristics of adults enrolled in the ongoing phase 3 randomized, double-blind, active-control trial of sparsentan for the treatment of immunoglobulin A nephropathy (PROTECT). Nephrol Dial Transplant 2022; 37 (Suppl. 3):i142–i144. https://academic.oup.com/ndt/article/37/Supplement_3/gfac067.008/6578479?login=false

• PubMed
Wong M, MO209: Baseline characteristics of adults enrolled in the ongoing phase 3 randomized, double-blind, active-control trial of sparsentan for the treatment of immunoglobulin A nephropathy (PROTECT). Nephrol Dial Transplant 2022; 37 (Suppl. 3):i142–i144. https://academic.oup.com/ndt/article/37/Supplement_3/gfac067.008/6578479?login=false )| false
• Search Google Scholar
• Export Citation

Wheeler DC, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 2021; 100:215–224. doi: 10.1016/j.kint.2021.03.033

• PubMed
Wheeler DC, A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 2021; 100:215–224. doi: 10.1016/j.kint.2021.03.033 )| false
• Search Google Scholar
• Export Citation

EMPA-KIDNEY Collaborative Group; Herrington WG, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med, published online ahead of print November 4, 2022. doi: 10.1056/NEJMoa2204233

• PubMed
EMPA-KIDNEY Collaborative Group; Herrington WG, Empagliflozin in patients with chronic kidney disease. N Engl J Med, published online ahead of print November 4, 2022. doi: 10.1056/NEJMoa2204233 )| false
• Search Google Scholar
• Export Citation

Cheung CK, et al. An update on the current state of management and clinical trials for IgA nephropathy. J Clin Med 2021; 10:2493. doi: 10.3390/jcm10112493

• PubMed
Cheung CK, An update on the current state of management and clinical trials for IgA nephropathy. J Clin Med 2021; 10:2493. doi: 10.3390/jcm10112493 )| false
• Search Google Scholar
• Export Citation